[
  {
    "ts": null,
    "headline": "Saudi Arabia In-Vitro Diagnostics Market Report 2025-2030 Featuring Abbott, BD, Bio-Rad Laboratories, Biomerieux, Danaher, Nihon Kohden, Roche, Siemens Healthineers, Sysmex, Thermo Fischer Scientific",
    "summary": "Saudi Arabia's in-vitro diagnostics market is set to grow from USD 734.7M in 2024 to USD 932.3M by 2030, driven by a rising elderly population and chronic disease prevalence. Saudi Arabia leads the GCC region in IVD, benefiting from government initiatives like Vision 2030 and healthcare sector advances.Dublin, July 16, 2025 (GLOBE NEWSWIRE) -- The \"Saudi Arabia In-Vitro Diagnostics (IVD) Market (By Segment, Application, Product, End User), Size, Share, Major Deals, Key Company Profiles, Revenue,",
    "url": "https://finnhub.io/api/news?id=bf23c91b3125a8fc6da0188499357f2b471441e15e0684c6346a178fff393f07",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752653220,
      "headline": "Saudi Arabia In-Vitro Diagnostics Market Report 2025-2030 Featuring Abbott, BD, Bio-Rad Laboratories, Biomerieux, Danaher, Nihon Kohden, Roche, Siemens Healthineers, Sysmex, Thermo Fischer Scientific",
      "id": 135965186,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Saudi Arabia's in-vitro diagnostics market is set to grow from USD 734.7M in 2024 to USD 932.3M by 2030, driven by a rising elderly population and chronic disease prevalence. Saudi Arabia leads the GCC region in IVD, benefiting from government initiatives like Vision 2030 and healthcare sector advances.Dublin, July 16, 2025 (GLOBE NEWSWIRE) -- The \"Saudi Arabia In-Vitro Diagnostics (IVD) Market (By Segment, Application, Product, End User), Size, Share, Major Deals, Key Company Profiles, Revenue,",
      "url": "https://finnhub.io/api/news?id=bf23c91b3125a8fc6da0188499357f2b471441e15e0684c6346a178fff393f07"
    }
  },
  {
    "ts": null,
    "headline": "Netflix, PepsiCo, J&J: Earnings to Come This Week",
    "summary": "Earnings season continues Wednesday with Bank of America, Goldman Sachs and others on the way. Big non-financial companies coming up include Johnson & Johnson, followed Thursday by Netflix and PepsiCo.",
    "url": "https://finnhub.io/api/news?id=31126113cfc6fff26dcac2aae34da8d42845ee151b8522b45614778181ae2cee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752651827,
      "headline": "Netflix, PepsiCo, J&J: Earnings to Come This Week",
      "id": 135965187,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Earnings season continues Wednesday with Bank of America, Goldman Sachs and others on the way. Big non-financial companies coming up include Johnson & Johnson, followed Thursday by Netflix and PepsiCo.",
      "url": "https://finnhub.io/api/news?id=31126113cfc6fff26dcac2aae34da8d42845ee151b8522b45614778181ae2cee"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer on Abbott: “Patience is a Virtue With ABT”",
    "summary": "Abbott Laboratories (NYSE:ABT) is one of the stocks that Jim Cramer shared insights on. While discussing the stock, Cramer recommended patience, as he commented: “Then one of my absolute favorite companies, medical device maker, Abbott Labs reports. And you know, I always like to tell you which companies tend to be misinterpreted in a negative […]",
    "url": "https://finnhub.io/api/news?id=414f261f25614cdd65d70313ad2b311769529df2a220218b15fabe7ce084068a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752638973,
      "headline": "Jim Cramer on Abbott: “Patience is a Virtue With ABT”",
      "id": 135965188,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories (NYSE:ABT) is one of the stocks that Jim Cramer shared insights on. While discussing the stock, Cramer recommended patience, as he commented: “Then one of my absolute favorite companies, medical device maker, Abbott Labs reports. And you know, I always like to tell you which companies tend to be misinterpreted in a negative […]",
      "url": "https://finnhub.io/api/news?id=414f261f25614cdd65d70313ad2b311769529df2a220218b15fabe7ce084068a"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Laboratories (ABT) Q2 Earnings: What To Expect",
    "summary": "Healthcare product and device company Abbott Laboratories (NYSE:ABT) will be announcing earnings results this Thursday morning. Here’s what investors should know.",
    "url": "https://finnhub.io/api/news?id=65701ac4e62734fabf879996e5bb49b5ed149ecb3228cc30aa934e27ab3e3775",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752635015,
      "headline": "Abbott Laboratories (ABT) Q2 Earnings: What To Expect",
      "id": 135965189,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Healthcare product and device company Abbott Laboratories (NYSE:ABT) will be announcing earnings results this Thursday morning. Here’s what investors should know.",
      "url": "https://finnhub.io/api/news?id=65701ac4e62734fabf879996e5bb49b5ed149ecb3228cc30aa934e27ab3e3775"
    }
  }
]